Stockreport

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Inc.  (SLDB) 
Last solid biosciences inc. earnings: 8/14 07:25 am Check Earnings Report
US:NASDAQ Investor Relations: investors.solidbio.com/investor-relations
PDF - IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participan [Read more]